AAPL312.47-3.75 (-1.19%) ▼|ABBV249.68+0.90 (+0.36%) ▲|ABT105.04-0.54 (-0.51%) ▼|ACN179.19+0.15 (+0.08%) ▲|ADBE257.55+0.29 (+0.11%) ▲|AMAT473.00+0.21 (+0.04%) ▲|AMD514.91+9.17 (+1.81%) ▲|AMGN390.88-2.29 (-0.58%) ▼|AMT175.45-0.30 (-0.17%) ▼|AMZN252.84-4.13 (-1.61%) ▼|AVGO364.32-4.24 (-1.15%) ▼|AXP322.50-3.62 (-1.11%) ▼|BA211.19+0.36 (+0.17%) ▲|BAC61.83-0.56 (-0.90%) ▼|BKNG173.01-7.30 (-4.05%) ▼|BLK1,088.81-7.02 (-0.64%) ▼|BMY64.44-0.26 (-0.40%) ▼|BNY161.52-1.35 (-0.83%) ▼|BRK-B502.72-3.10 (-0.61%) ▼|C135.65-1.13 (-0.82%) ▼|CAT825.99+3.46 (+0.42%) ▲|CL87.45-0.96 (-1.09%) ▼|CMCSA26.06-0.27 (-1.03%) ▼|COF212.80-1.23 (-0.57%) ▼|COP136.61+1.56 (+1.16%) ▲|COST902.98-7.20 (-0.79%) ▼|CRM251.15+1.97 (+0.79%) ▲|CSCO109.96+0.79 (+0.72%) ▲|CVS96.34+0.25 (+0.26%) ▲|CVX213.35+3.35 (+1.60%) ▲|DE684.82+4.02 (+0.59%) ▲|DHR202.86-2.33 (-1.13%) ▼|DIS103.47-1.63 (-1.55%) ▼|DUK121.40+0.15 (+0.12%) ▲|EMR151.94-0.24 (-0.16%) ▼|FDX310.75-3.36 (-1.07%) ▼|GD356.58+0.03 (+0.01%) ▲|GE329.16-5.78 (-1.73%) ▼|GEV982.00+10.62 (+1.09%) ▲|GILD145.73-0.92 (-0.62%) ▼|GM85.56-0.22 (-0.26%) ▼|GOOG327.29-8.09 (-2.41%) ▼|GOOGL329.68-8.69 (-2.57%) ▼|GS1,017.52-19.16 (-1.85%) ▼|HD311.06-2.61 (-0.83%) ▼|HON208.03-0.21 (-0.10%) ▼|IBM235.36+3.25 (+1.40%) ▲|INTC103.88-0.59 (-0.56%) ▼|INTU320.05+1.12 (+0.35%) ▲|ISRG353.50+3.34 (+0.95%) ▲|JNJ268.79-0.39 (-0.14%) ▼|JPM351.52-2.03 (-0.57%) ▼|KO87.77-0.66 (-0.74%) ▼|LIN467.79-0.59 (-0.13%) ▼|LLY1,131.65+7.79 (+0.69%) ▲|LMT538.72+2.40 (+0.45%) ▲|LOW199.94-0.88 (-0.44%) ▼|LRCX320.58+0.16 (+0.05%) ▲|MA566.56-4.38 (-0.77%) ▼|MCD253.85-1.99 (-0.78%) ▼|MDLZ61.01-0.62 (-1.01%) ▼|MDT92.18-0.22 (-0.23%) ▼|META643.68+30.20 (+4.92%) ▲|MMM166.19-1.33 (-0.79%) ▼|MO67.57-0.61 (-0.89%) ▼|MRK148.14-0.34 (-0.23%) ▼|MS213.88-2.43 (-1.12%) ▼|MSFT492.73-1.22 (-0.25%) ▼|MU1,001.54+1.28 (+0.13%) ▲|NEE84.19+0.34 (+0.40%) ▲|NFLX76.60-0.17 (-0.22%) ▼|NKE37.17-0.93 (-2.45%) ▼|NOW133.49-0.75 (-0.56%) ▼|NVDA225.19-0.54 (-0.24%) ▼|ORCL162.35-0.17 (-0.10%) ▼|PEP137.42-1.03 (-0.74%) ▼|PFE27.63-0.17 (-0.61%) ▼|PG142.72-2.87 (-1.97%) ▼|PLTR170.35+0.05 (+0.03%) ▲|PM181.57-3.21 (-1.74%) ▼|QCOM179.87+5.78 (+3.32%) ▲|RTX198.29-0.55 (-0.28%) ▼|SBUX100.49-1.52 (-1.49%) ▼|SCHW107.04+0.17 (+0.16%) ▲|SO88.82-0.19 (-0.21%) ▼|SPG209.90+0.18 (+0.09%) ▲|T25.26-0.36 (-1.39%) ▼|TMO598.34-4.92 (-0.82%) ▼|TMUS181.01-0.68 (-0.37%) ▼|TSLA371.53+3.37 (+0.91%) ▲|TXN258.87-0.05 (-0.02%) ▼|UBER72.64-0.50 (-0.68%) ▼|UNH393.21-7.66 (-1.91%) ▼|UNP285.45-3.42 (-1.18%) ▼|UPS100.00-0.48 (-0.48%) ▼|USB62.07-0.44 (-0.70%) ▼|V367.71-1.11 (-0.30%) ▼|VZ49.86-0.54 (-1.07%) ▼|WFC88.22+0.25 (+0.28%) ▲|WMT105.36-0.70 (-0.66%) ▼|XOM164.76+4.05 (+2.52%) ▲|AAPL312.47-3.75 (-1.19%) ▼|ABBV249.68+0.90 (+0.36%) ▲|ABT105.04-0.54 (-0.51%) ▼|ACN179.19+0.15 (+0.08%) ▲|ADBE257.55+0.29 (+0.11%) ▲|AMAT473.00+0.21 (+0.04%) ▲|AMD514.91+9.17 (+1.81%) ▲|AMGN390.88-2.29 (-0.58%) ▼|AMT175.45-0.30 (-0.17%) ▼|AMZN252.84-4.13 (-1.61%) ▼|AVGO364.32-4.24 (-1.15%) ▼|AXP322.50-3.62 (-1.11%) ▼|BA211.19+0.36 (+0.17%) ▲|BAC61.83-0.56 (-0.90%) ▼|BKNG173.01-7.30 (-4.05%) ▼|BLK1,088.81-7.02 (-0.64%) ▼|BMY64.44-0.26 (-0.40%) ▼|BNY161.52-1.35 (-0.83%) ▼|BRK-B502.72-3.10 (-0.61%) ▼|C135.65-1.13 (-0.82%) ▼|CAT825.99+3.46 (+0.42%) ▲|CL87.45-0.96 (-1.09%) ▼|CMCSA26.06-0.27 (-1.03%) ▼|COF212.80-1.23 (-0.57%) ▼|COP136.61+1.56 (+1.16%) ▲|COST902.98-7.20 (-0.79%) ▼|CRM251.15+1.97 (+0.79%) ▲|CSCO109.96+0.79 (+0.72%) ▲|CVS96.34+0.25 (+0.26%) ▲|CVX213.35+3.35 (+1.60%) ▲|DE684.82+4.02 (+0.59%) ▲|DHR202.86-2.33 (-1.13%) ▼|DIS103.47-1.63 (-1.55%) ▼|DUK121.40+0.15 (+0.12%) ▲|EMR151.94-0.24 (-0.16%) ▼|FDX310.75-3.36 (-1.07%) ▼|GD356.58+0.03 (+0.01%) ▲|GE329.16-5.78 (-1.73%) ▼|GEV982.00+10.62 (+1.09%) ▲|GILD145.73-0.92 (-0.62%) ▼|GM85.56-0.22 (-0.26%) ▼|GOOG327.29-8.09 (-2.41%) ▼|GOOGL329.68-8.69 (-2.57%) ▼|GS1,017.52-19.16 (-1.85%) ▼|HD311.06-2.61 (-0.83%) ▼|HON208.03-0.21 (-0.10%) ▼|IBM235.36+3.25 (+1.40%) ▲|INTC103.88-0.59 (-0.56%) ▼|INTU320.05+1.12 (+0.35%) ▲|ISRG353.50+3.34 (+0.95%) ▲|JNJ268.79-0.39 (-0.14%) ▼|JPM351.52-2.03 (-0.57%) ▼|KO87.77-0.66 (-0.74%) ▼|LIN467.79-0.59 (-0.13%) ▼|LLY1,131.65+7.79 (+0.69%) ▲|LMT538.72+2.40 (+0.45%) ▲|LOW199.94-0.88 (-0.44%) ▼|LRCX320.58+0.16 (+0.05%) ▲|MA566.56-4.38 (-0.77%) ▼|MCD253.85-1.99 (-0.78%) ▼|MDLZ61.01-0.62 (-1.01%) ▼|MDT92.18-0.22 (-0.23%) ▼|META643.68+30.20 (+4.92%) ▲|MMM166.19-1.33 (-0.79%) ▼|MO67.57-0.61 (-0.89%) ▼|MRK148.14-0.34 (-0.23%) ▼|MS213.88-2.43 (-1.12%) ▼|MSFT492.73-1.22 (-0.25%) ▼|MU1,001.54+1.28 (+0.13%) ▲|NEE84.19+0.34 (+0.40%) ▲|NFLX76.60-0.17 (-0.22%) ▼|NKE37.17-0.93 (-2.45%) ▼|NOW133.49-0.75 (-0.56%) ▼|NVDA225.19-0.54 (-0.24%) ▼|ORCL162.35-0.17 (-0.10%) ▼|PEP137.42-1.03 (-0.74%) ▼|PFE27.63-0.17 (-0.61%) ▼|PG142.72-2.87 (-1.97%) ▼|PLTR170.35+0.05 (+0.03%) ▲|PM181.57-3.21 (-1.74%) ▼|QCOM179.87+5.78 (+3.32%) ▲|RTX198.29-0.55 (-0.28%) ▼|SBUX100.49-1.52 (-1.49%) ▼|SCHW107.04+0.17 (+0.16%) ▲|SO88.82-0.19 (-0.21%) ▼|SPG209.90+0.18 (+0.09%) ▲|T25.26-0.36 (-1.39%) ▼|TMO598.34-4.92 (-0.82%) ▼|TMUS181.01-0.68 (-0.37%) ▼|TSLA371.53+3.37 (+0.91%) ▲|TXN258.87-0.05 (-0.02%) ▼|UBER72.64-0.50 (-0.68%) ▼|UNH393.21-7.66 (-1.91%) ▼|UNP285.45-3.42 (-1.18%) ▼|UPS100.00-0.48 (-0.48%) ▼|USB62.07-0.44 (-0.70%) ▼|V367.71-1.11 (-0.30%) ▼|VZ49.86-0.54 (-1.07%) ▼|WFC88.22+0.25 (+0.28%) ▲|WMT105.36-0.70 (-0.66%) ▼|XOM164.76+4.05 (+2.52%) ▲|
22.5 C
New York
Wednesday, September 9, 2026

Tag: pharmaceuticals

QNET Unveils Wellness Breakthroughs and Global Empowerment at V-Malaysia 2025

Over 8,000 global entrepreneurs gather in Penang for five days of wellness innovation and mentorship. HONG KONG, July 11, 2025 /PRNewswire/ -- QNET kicked off...

Novartis and the pan-Canadian Pharmaceutical Alliance achieve milestone agreement on Cosentyx® for hidradenitis suppurativa (HS)

Important milestone towards public reimbursement for a new treatment option for eligible Canadian patients living with moderate to severe hidradenitis suppurativa (HS)Following this important...

Diagnostics Transformed: $37 Billion Immunoassay Market Evolves with AI, Miniaturization, and POC Growth, reports Kalorama Information

ARLINGTON, Va., July 10, 2025 /PRNewswire/ -- Kalorama Information, a leading healthcare market intelligence firm, has published a comprehensive new report, Global Immunoassay Market:...

Acumen Pharmaceuticals to Present Studies on Cost Savings Associated with Use of pTau217 Screening Assay in Phase 2 ALTITUDE-AD Study and Sabirnetug Oligomer-Selectivity at...

NEWTON, Mass., July 10, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), will present new findings at the upcoming Alzheimer's Association International Conference (AAIC®) 2025 in Toronto. The presentations include a cost savings analysis of the use of pTau217 as a screening tool in Acumen’s Phase 2 ALTITUDE-AD trial of sabirnetug as well as a nonclinical study evaluating the relative selectivity of sabirnetug to targeting AβOs versus Aβ monomers. The conference will be held July 27-31, 2025, both in-person and online.

Varda Announces $187 million in Series C Funding to Make Medicines in Space

The El Segundo-based start-up is building infrastructure to support manufacturing in microgravity and test hypersonic reentry technologies. EL SEGUNDO, Calif., July 10, 2025 /PRNewswire/ -- Varda...

Phosphorous Trichloride Market worth $3.46 billion by 2030 – Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., July 10, 2025 /PRNewswire/ -- The report "Phosphorous Trichloride Market by Application (Plastic Additives, Agrochemicals and Pharmaceuticals, Surfactants, Flame Retardants, Oil &...

Phosphorous Trichloride Market worth $3.46 billion by 2030 – Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., July 10, 2025 /PRNewswire/ -- The report "Phosphorous Trichloride Market by Application (Plastic Additives, Agrochemicals and Pharmaceuticals, Surfactants, Flame Retardants, Oil &...

[Latest] Global Pet Oral Care Products Market Size/Share Worth USD 3,583.11 Million by 2034 at a 5.73% CAGR: Custom Market Insights (Analysis, Outlook, Leaders,...

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Pet Oral Care Products Market size & share revenue was valued at approximately USD 2,056.87 Million in 2024 and is expected to reach USD 2,169.79 Million in 2025 and is expected to reach around USD 3,583.11 Million by 2034, at a CAGR of 5.73% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are All4pets, AllAccem Inc., Central Garden & Pet Company, Ceva, Ceva Santé Animale, Cosmos Corporation, Dechra Pharmaceuticals plc, Goran Pharma Pvt. Ltd., Hill’s Pet Nutrition Inc., Imrex Inc., Kane Biotech, Inc., Mars Incorporated, Nestlé Purina PetCare Company (Nestlé S.A.), Petzlife UK, Vetoquinol SA, Virbac and others.
[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Pet Oral Care Products Market size & share revenue was valued at approximately USD 2,056.87 Million in 2024 and is expected to reach USD 2,169.79 Million in 2025 and is expected to reach around USD 3,583.11 Million by 2034, at a CAGR of 5.73% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are All4pets, AllAccem Inc., Central Garden & Pet Company, Ceva, Ceva Santé Animale, Cosmos Corporation, Dechra Pharmaceuticals plc, Goran Pharma Pvt. Ltd., Hill’s Pet Nutrition Inc., Imrex Inc., Kane Biotech, Inc., Mars Incorporated, Nestlé Purina PetCare Company (Nestlé S.A.), Petzlife UK, Vetoquinol SA, Virbac and others.

DKSH and Bayer Launch Strategic Partnership Across Multiple Markets in Southeast Asia

DKSH has signed a strategic business partnership with life science company Bayer, to provide comprehensive services for a portion of the Bayer Pharmaceuticals business in...

Gozellix Receives Permanent HCPCS Code

MELBOURNE, Australia and INDIANAPOLIS, July 10, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that its next-generation PSMA1 PET2 imaging agent, Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection), has been granted a permanent Healthcare Common Procedure Coding System (HCPCS) code by the U.S. Centers for Medicare & Medicaid Services (CMS).

Cancer Cachexia Market Anticipates Impressive Growth Trajectory at a CAGR of 8.9% During the Forecast Period (2025-2034) | DelveInsight

The cancer cachexia market is expected to witness an expansion across the 7MM, driven by the introduction of innovative therapies, ponsegromab (PF-06946860), S-pindolol benzoate...

Cancer Cachexia Market Anticipates Impressive Growth Trajectory at a CAGR of 8.9% During the Forecast Period (2025-2034) | DelveInsight

The cancer cachexia market is expected to witness an expansion across the 7MM, driven by the introduction of innovative therapies, ponsegromab (PF-06946860), S-pindolol benzoate...

Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock

BOSTON, July 09, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) (“Rhythm”), a global, commercial-stage biopharmaceutical company dedicated to transforming the lives of patients living with rare neuroendocrine diseases, today announced a proposed public offering of $150 million of its common stock. All securities in the offering will be offered by Rhythm. In addition, Rhythm intends to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of shares of common stock at the public offering price, less the underwriting discounts and commissions.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPharmaceuticals